Henry Schein (NASDAQ:HSIC) PT Raised to $74.00 at Evercore ISI

Henry Schein (NASDAQ:HSIC) had its target price lifted by analysts at Evercore ISI from $70.00 to $74.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has an “in-line” rating on the stock. Evercore ISI’s price objective indicates a potential upside of 6.15% from the company’s previous close.

Several other brokerages have also issued reports on HSIC. UBS Group decreased their price target on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Baird R W upgraded Henry Schein from a “hold” rating to a “strong-buy” rating in a report on Monday, July 22nd. JPMorgan Chase & Co. cut their price objective on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. Barrington Research reissued an “outperform” rating and set a $82.00 target price on shares of Henry Schein in a research note on Friday, September 20th. Finally, Robert W. Baird cut their price target on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $77.50.

Henry Schein Trading Up 0.6 %

Shares of Henry Schein stock traded up $0.41 during trading on Tuesday, reaching $69.71. 219,945 shares of the company were exchanged, compared to its average volume of 1,341,730. The business has a 50-day moving average price of $70.11 and a 200-day moving average price of $70.04. The firm has a market capitalization of $8.93 billion, a price-to-earnings ratio of 23.59, a P/E/G ratio of 2.01 and a beta of 0.86. The company has a quick ratio of 0.90, a current ratio of 1.55 and a debt-to-equity ratio of 0.46. Henry Schein has a twelve month low of $60.01 and a twelve month high of $82.63.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, August 6th. The company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.01. The company had revenue of $3.10 billion during the quarter, compared to analyst estimates of $3.27 billion. Henry Schein had a return on equity of 13.19% and a net margin of 2.82%. The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.31 EPS. Sell-side analysts anticipate that Henry Schein will post 4.74 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Lorelei Mcglynn sold 21,035 shares of the firm’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the completion of the transaction, the senior vice president now directly owns 71,833 shares of the company’s stock, valued at approximately $4,978,026.90. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.14% of the company’s stock.

Hedge Funds Weigh In On Henry Schein

Hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC raised its position in shares of Henry Schein by 167.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 19,872 shares of the company’s stock valued at $1,505,000 after purchasing an additional 12,452 shares during the period. Crossmark Global Holdings Inc. lifted its position in Henry Schein by 1.5% during the fourth quarter. Crossmark Global Holdings Inc. now owns 13,090 shares of the company’s stock worth $991,000 after acquiring an additional 197 shares during the last quarter. Cibc World Markets Corp boosted its holdings in shares of Henry Schein by 133.1% during the fourth quarter. Cibc World Markets Corp now owns 16,802 shares of the company’s stock worth $1,272,000 after acquiring an additional 9,595 shares during the period. Cresset Asset Management LLC grew its position in shares of Henry Schein by 10.8% in the fourth quarter. Cresset Asset Management LLC now owns 115,570 shares of the company’s stock valued at $8,750,000 after purchasing an additional 11,302 shares during the last quarter. Finally, Bridgewater Associates LP increased its stake in shares of Henry Schein by 15.9% during the fourth quarter. Bridgewater Associates LP now owns 258,902 shares of the company’s stock worth $19,601,000 after purchasing an additional 35,548 shares during the period. Institutional investors own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.